nach oben

Journal of Cancer Research and Clinical Oncology

Erschienen in:

23.01.2019 | Review – Clinical Oncology

Mistletoe in oncological treatment: a systematic review

Part 1: survival and safety

verfasst von: M. Freuding, C. Keinki, O. Micke, J. Buentzel, Jutta Huebner

Erschienen in: Journal of Cancer Research and Clinical Oncology | Ausgabe 3/2019

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Mistletoe treatment of cancer patients is discussed highly controversial in the scientific literature. Aim of this systematic review is to give an extensive overview about current state of research concerning mistletoe therapy of oncologic patients regarding survival, quality of life and safety.

Methods

In September and October 2017 Medline, Embase, Cochrane Central Register of Controlled Trials (CENTRAL), PsycINFO, CINAHL and “Science Citation Index Expanded” (Web of Science) were systematically searched.

Results

The search strategy identified 3647 hits and 28 publications with 2639 patients were finally included in this review. Mistletoe was used in bladder cancer, breast cancer, other gynecological cancers (cervical cancer, corpus uteri cancer, and ovarian cancer), colorectal cancer, other gastrointestinal cancer (gastric cancer and pancreatic cancer), glioma, head and neck cancer, lung cancer, melanoma and osteosarcoma. In nearly all studies, mistletoe was added to a conventional therapy. Patient relevant endpoints were overall survival (14 studies, n = 1054), progression- or disease-free survival or tumor response (10 studies, n = 1091). Most studies did not show any effect of mistletoe on survival. Especially high quality studies do not show any benefit.

Conclusions

With respect to survival, a thorough review of the literature does not provide any indication to prescribe mistletoe to patients with cancer.

Nur mit Berechtigung zugänglich

Abreu P, Sanchez R, Mut T, Balaguer D, Latorre I, Rodriguez H (2017) Homeopathic mistletoe adverse reaction mimics nodal involvement in 18F-FDG PET/CT performed for evaluation of response to chemotherapy in lymphoma. Revista Espanola de Medicina Nuclear e Imagen Molecular 36:110–112. https://doi.org/10.1016/j.remn.2016.07.005 CrossRefPubMed

Bar-Sela G, Wollner M, Hammer L, Agbarya A, Dudnik E, Haim N (2013) Mistletoe as complementary treatment in patients with advanced non-small-cell lung cancer treated with carboplatin-based combinations: a randomised phase II study. Eur J Cancer 49:1058–1064CrossRefPubMed

Bussing A, Raak C, Ostermann T (2012) Quality of life and related dimensions in cancer patients treated with mistletoe extract (iscador): a meta-analysis. Evid Based Complement Altern Med eCAM 2012. https://doi.org/10.1155/2012/219402 CrossRef

Cazacu M et al (2003) The influence of isorel on the advanced colorectal cancer. Cancer Biother Radiopharm 18:27–34CrossRefPubMed

Conrad AC, Muenstedt K, Micke O, Prott FJ, Muecke R, Huebner J (2014) Attitudes of members of the German Society for Palliative Medicine toward complementary and alternative medicine for cancer patients. J Cancer Res Clin Oncol 140:1229–1237. https://doi.org/10.1007/s00432-014-1656-9 CrossRefPubMed

El-Kolaly RM, Abo-Elnasr M, El-Guindy D (2016) Outcome of pleurodesis using different agents in management of malignant pleural effusion Egyptian. J Chest Dis Tuberc 65:435–440CrossRef

Ernst E, Schmidt K, Steuer-Vogt MK (2003) Mistletoe for cancer? A systematic review of randomised clinical trials. Int J Cancer 107:262–267CrossRefPubMed

Gaafar R, Abdel Rahman ARM, Aboulkasem F, El Bastawisy A (2014) Mistletoe preparation (Viscum Fraxini-2) as palliative treatment for malignant pleural effusion: a feasibility study with comparison to bleomycin. Ecancermedicalscience 8:424. https://doi.org/10.3332/ecancer.2014.424 CrossRefPubMedPubMedCentral

Goebell PJ, Otto T, Suhr J, Rubben H (2002) Evaluation of an unconventional treatment modality with mistletoe lectin to prevent recurrence of superficial bladder cancer: a randomized phase II trial. J Urol 168:72–75CrossRefPubMed

Grossarth-Maticek R, Ziegler R (2006a) Prospective controlled cohort studies on long-term therapy of breast cancer patients with a mistletoe preparation (Iscador). Forschende Komplementarmedizin (2006) 13:285–292

Grossarth-Maticek R, Ziegler R (2006b) Randomised and non-randomised prospective controlled cohort studies in matched-pair design for the long-term therapy of breast cancer patients with a mistletoe preparation (Iscador): a re-analysis. Eur J Med Res 11:485–495PubMed

Grossarth-Maticek R, Ziegler R (2007a) Efficacy and safety of the long-term treatment of melanoma with a mistletoe preparation (Iscador). Schweizerische Zeitschrift fur GanzheitsMedizin [German] 19:325–332CrossRef

Grossarth-Maticek R, Ziegler R (2007b) Prospective controlled cohort studies on long-term therapy of cervical cancer patients with a mistletoe preparation (Iscador) Forschende Komplementarmedizin (2006) 14:140–147

Grossarth-Maticek R, Ziegler R (2007c) Prospective controlled cohort studies on long-term therapy of ovairian cancer patients with mistletoe (Viscum album L.) extracts iscador. Arzneimittelforschung 57:665–678PubMed

Grossarth-Maticek R, Ziegler R (2008) Randomized and non-randomized prospective controlled cohort studies in matched pair design for the long-term therapy of corpus uteri cancer patients with a mistletoe preparation (Iscador). Eur J Med Res 13:107–120PubMed

Grossarth-Maticek R, Kiene H, Baumgartner SM, Ziegler R (2001) Use of Iscador, an extract of European mistletoe (Viscum album), in cancer treatment: prospective nonrandomized and randomized matched-pair studies nested within a cohort study. Altern Ther Health Med 7:57–66 (68–72, 74–56 passim)PubMed

Hagenah W, Dorges I, Gafumbegete E, Wagner T (1998) Subcutaneous manifestations of a centrocytic non-Hodgkin lymphoma at the injection site of a mistletoe preparation. Deutsche medizinische Wochenschrift (1946) 123:1001–1004 https://doi.org/10.1055/s-2007-1024111 CrossRef

Heiny BM, Albrecht V (1997) Complementary modes of therapy with mistletoe lectin-1. Medizinische Welt [German] 48:419–423

Heiny BM, Albrecht V, Beuth J (1998) Correlation of immune cell activities and beta-endorphin release in breast carcinoma patients treated with galactose-specific lectin standardized mistletoe extract. Anticancer Res 18:583–586PubMed

Henf A, Wesselmann S, Huthmann D, Muenstedt K, Huebner J, On behalf of the Working Group P, Intergrative Oncology of the German Cancer Society J (2014) Complementary and alternative medicine in German Cancer Centers. Oncol Res Treat 37:390–394. https://doi.org/10.1159/000364897 CrossRef

Higgins JPT, Altman DG, Sterne JAC (2017) Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Churchill R, Chandler J, Cumpston MS (eds) Cochrane Handbook for Systematic Reviews of Interventions version 5.2.0 (updated June 2017). Cochrane

Horneber MA, Bueschel G, Huber R, Linde K, Rostock M (2008) Mistletoe therapy in oncology Cochrane Database of Syst Revi 107:CD003297

Hubner J, Phieler F (2009) Hypersensitivity reaction to oxaliplatinum recurrence during mistletoe therapy? Tumor Diagnostik Therapie [German] 30:36–39

Huebner J (2008) Komplementäre Onkologie - Supportive Maßnahmen und evidenzbasierte Empfehlungen. Schattauer, Stuttgart

Hutt N, Kopferschmitt-Kubler M, Cabalion J, Purohit A, Alt M, Pauli G (2001) Anaphylactic reactions after therapeutic injection of mistletoe (Viscum album L.). Allergologia et immunopathologia 29:201–203CrossRefPubMed

Kienle GS, Kiene H (2007) Complementary cancer therapy: a systematic review of prospective clinical trials on anthroposophic mistletoe extracts. Eur J Med Res 12:103–119PubMed

Kienle GS, Kiene H (2010) Review article: Influence of Viscum album L (European mistletoe) extracts on quality of life in cancer patients: a systematic review of controlled clinical studies. Integr Cancer Ther 9:142–157CrossRefPubMed

Kienle GS, Glockmann A, Schink M, Kiene H (2009) Viscum album L. extracts in breast and gynaecological cancers: a systematic review of clinical and preclinical research. J Exp Clin Cancer Res 28:79CrossRefPubMedPubMedCentral

Kim KC, Yook JH, Eisenbraun J, Kim BS, Huber R (2012) Quality of life, immunomodulation and safety of adjuvant mistletoe treatment in patients with gastric carcinoma—a randomized, controlled pilot study. BMC Complement Altern Med 12:172CrossRefPubMedPubMedCentral

Kleeberg UR et al (2004) Final results of the EORTC 18871/DKG 80-1 randomised phase III trial. rIFN-alpha2b versus rIFN-gamma versus ISCADOR M versus observation after surgery in melanoma patients with either high-risk primary (thickness> 3 mm) or regional lymph node metastasis. Eur J Cancer 40:390–402CrossRef

Lange-Lindberg A-M, Velasco Garrido M, Busse R (2006) Mistletoe treatments for minimising side effects of anticancer chemotherapy. GMS Health Technol Assess 2:Doc18PubMedPubMedCentral

Lenartz D, Stoffel B, Menzel J, Beuth J (1996) Immunoprotective activity of the galactoside-specific lectin from mistletoe after tumor destructive therapy in glioma patients. Anticancer Res 16:3799–3802PubMed

Lenartz D, Dott U, Menzel J, Schierholz JM, Beuth J (2000) Survival of glioma patients after complementary treatment with galactoside-specific lectin from mistletoe. Anticancer Res 20:2073–2076PubMed

Longhi A, Reif M, Mariani E, Ferrari S (2014) a randomized study on postrelapse disease-free survival with adjuvant mistletoe versus oral etoposide in osteosarcoma patients. Evid Based Complement Altern Med eCAM 2014. https://doi.org/10.1155/2014/210198 CrossRef

Melzer J, Iten F, Hostanska K, Saller R (2009) Efficacy and safety of mistletoe preparations (Viscum album) for patients with cancer diseases. A systematic review. Forschende Komplementarmedizin (2006) 16:217–226

Ostermann T, Bussing A (2012) Retrolective studies on the survival of cancer patients treated with mistletoe extracts: a meta-analysis. Explore J Sci Heal 8:277–281

Ostermann T, Raak C, Bussing A (2009) Survival of cancer patients treated with mistletoe extract (Iscador): a systematic literature review. BMC Cancer 9:451CrossRefPubMedPubMedCentral

Ott IM et al (2015) Attitude of oncology/hematology nurses from German speaking countries towards complementary and alternative medicine. Trace Elem Electrolytes 32:74–80CrossRef

Piao BK, Wang YX, Xie GR, Mansmann U, Matthes H, Beuth J, Lin HS (2004) Impact of complementary mistletoe extract treatment on quality of life in breast, ovarian and non-small cell lung cancer patients. A prospective randomized controlled clinical trial. Anticancer Res 24:303–309PubMed

Robinson A, McGrail MR (2004) Disclosure of CAM use to medical practitioners: a review of qualitative and quantitative studies. Complement Ther Med 12:90–98. https://doi.org/10.1016/j.ctim.2004.09.006 CrossRefPubMed

Saxe GA, Madlensky L, Kealey S, Wu DP, Freeman KL, Pierce JP (2008) Disclosure to physicians of CAM use by breast cancer patients: findings from the Women’s Healthy Eating and Living Study. Integr Cancer Ther 7:122–129. https://doi.org/10.1177/1534735408323081 CrossRefPubMedPubMedCentral

Schierholz JM et al (2003) Complementary cancer therapy with standardized mistletoe extracts. Results of a controlled prospective multicentric randomized clinical trial. [German] Deutsche Zeitschrift fur Onkologie 35:186–194CrossRef

Schink M et al (2007) Mistletoe extract reduces the surgical suppression of natural killer cell activity in cancer patients. a randomized phase III trial. Forschende Komplementarmedizin (2006) 14:9–17

Semiglasov VF, Stepula VV, Dudov A, Lehmacher W, Mengs U (2004) The standardised mistletoe extract PS76A2 improves QoL in patients with breast cancer receiving adjuvant CMF chemotherapy: a randomised, placebo-controlled, double-blind multicentre clinical trial. Anticancer Res 24:1293–1302PubMed

Semiglasov VF, Stepula VV, Dudov A, Schnitker J, Mengs U (2006) Quality of life is improved in breast cancer patients by Standardised Mistletoe Extract PS76A2 during chemotherapy and follow-up: a randomised, placebo-controlled, double-blind multicentre clinical trial. Anticancer Res 26:1519–1529

Shaw HS, Hobbs KB, Kroll DJ, Seewaldt VL (2004) Delayed-type hypersensitivity reaction with iscador M given in combination with cytotoxic chemotherapy. J Clin Oncol 22:4432–4434. https://doi.org/10.1200/jco.2004.04.140 CrossRefPubMed

Steele ML, Axtner J, Happe A, Kroz M, Matthes H, Schad F (2014) Adverse drug reactions and expected effects to therapy with subcutaneous mistletoe extracts (Viscum album L.) in cancer patients. Evid Based Complement Altern Med eCAM 2014. https://doi.org/10.1155/2014/724258 CrossRef

Steuer-Vogt MK et al (2001) The effect of an adjuvant mistletoe treatment programme in resected head and neck cancer patients: a randomised controlled clinical trial European. J Cancer 37:23–31

Steuer-Vogt MK, Bonkowsky V, Scholz M, Fauser C, Licht K, Ambrosch P (2006) Influence of ML-1 standardized mistletoe extract on the quality of life in head and neck cancer patients. Hno 54:277–286CrossRefPubMed

Styczynski J, Wysocki M (2006) Alternative medicine remedies might stimulate viability of leukemic cells. Pediatr Blood Cancer 46:94–98. https://doi.org/10.1002/pbc.20513 CrossRefPubMed

Thies A, Nugel D, Pfuller U, Moll I, Schumacher U (2005) Influence of mistletoe lectins and cytokines induced by them on cell proliferation of human melanoma cells in vitro. Toxicology 207:105–116. https://doi.org/10.1016/j.tox.2004.09.009 CrossRefPubMed

Thronicke A, Steele M, Grah C, Matthes B, Schad F (2017) Clinical safety of combinational therapy of immune checkpoint inhibitors and Viscum album L. in patients with advanced or metastasized cancer. Journal of Thorac Oncol 12(1 Supplement 1):S1295–S1296CrossRef

Trimborn A et al (2013) Attitude of employees of a university clinic to complementary and alternative medicine in oncology. Ann Oncology 24:2641–2645. https://doi.org/10.1093/annonc/mdt299 CrossRef

Troger W (2011) Connection between quality of life and neutropenia in breast cancer patients who were solely treated with chemotherapy or additionally with mistletoe therapy: results of a randomized study. Deutsche Zeitschrift fur Onkologie [German] 43:58–67CrossRef

Troger W, Jezdic S, Zdrale Z, Tisma N, Hamre HJ, Matijasevic M (2009) Quality of life and neutropenia in patients with early stage breast cancer: a randomized pilot study comparing additional treatment with mistletoe extract to chemotherapy alone. Breast Cancer Basic Clin Res 3:35–45CrossRef

Troger W, Zdrale Z, Stankovic N, Matijasevic M (2012) Five-year follow-up of patients with early stage breast cancer after a randomized study comparing additional treatment with Viscum album (L.) extract to chemotherapy alone. Breast Cancer Basic Clin Res 6:173–180. https://doi.org/10.4137/BCBCR.S10558 CrossRef

Troger W, Galun D, Reif M, Schumann A, Stankovic N, Milicevic M (2013) Viscum album [L.] extract therapy in patients with locally advanced or metastatic pancreatic cancer: a randomised clinical trial on overall survival European. J Cancer 49:3788–3797

Troger W, Galun D, Reif M, Schumann A, Stankovic N, Milicevic M (2014a) Quality of life of patients with advanced pancreatic cancer during treatment with mistletoe: a randomized controlled trial. Deutsch Arzteblatt Int 111:493–502

Troger W, Zdrale Z, Tisma N, Matijasevic M (2014b) Additional therapy with a mistletoe product during adjuvant chemotherapy of breast cancer patients improves quality of life: an open randomized clinical pilot trial. Evid Based Complement Altern Med eCAM 2014. https://doi.org/10.1155/2014/430518 CrossRef

Troger W, Zdrale Z, Stankovic N (2016) Five-Year follow-up of patients with early stage breast cancer after a randomized study with Viscum album (L.) extract. [German]. Deutsche Zeitschrift fur Onkologie 48:105–110CrossRef

Tröger W, Galun D, Reif M, Schumann A, Stankovi N, Milićevi M (2013) Viscum album [L.] extract therapy in patients with locally advanced or metastatic pancreatic cancer: a randomised clinical trial on overall survival. Eur J Cancer (Oxford Engl 1990) 49:3788–3797. https://doi.org/10.1016/j.ejca.2013.06.043 CrossRef

Tröger W, Galun D, Reif M, Schumann A, Stankovi N, Milićevi M (2014) Quality of life of patients with advanced pancreatic cancer during treatment with mistletoe: a randomized controlled trial. Deutsch Arzteblatt Int 111:493–502. https://doi.org/10.3238/arztebl.2014.0493 CrossRef

Titel: Mistletoe in oncological treatment: a systematic review
Part 1: survival and safety
verfasst von: M. Freuding
C. Keinki
O. Micke
J. Buentzel
Jutta Huebner
Publikationsdatum: 23.01.2019
Verlag: Springer Berlin Heidelberg
Erschienen in: Journal of Cancer Research and Clinical Oncology / Ausgabe 3/2019
Print ISSN: 0171-5216
Elektronische ISSN: 1432-1335
DOI: https://doi.org/10.1007/s00432-018-02837-4

Springer Medizin

Mistletoe in oncological treatment: a systematic review

Part 1: survival and safety

Abstract

Purpose

Methods

Results

Conclusions

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2019

Effect of the botanical formula LCS101 on the anti-cancer effects of radiation therapy

LncRNA GAS5 regulates redox balance and dysregulates the cell cycle and apoptosis in malignant melanoma cells

Pre-orchiectomy tumor marker levels should not be used for International Germ Cell Consensus Classification (IGCCCG) risk group assignment

Identification of genes and pathways, including the CXCL2 axis, altered by DNA methylation in hepatocellular carcinoma

Comparative analysis of co-occurring mutations of specific tumor suppressor genes in lung adenocarcinoma between Asian and Caucasian populations

Increasing trends in in situ breast cancer incidence in a region with no population-based mammographic screening program: results from Zurich, Switzerland 2003–2014

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie